Jiangxi Synergy Pharmaceutical Co Ltd (SHE:300636) — Market Cap & Net Worth
Market Cap & Net Worth: Jiangxi Synergy Pharmaceutical Co Ltd (300636)
Jiangxi Synergy Pharmaceutical Co Ltd (SHE:300636) has a market capitalization of $412.34 Million (CN¥2.82 Billion) as of September 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #13363 globally and #3990 in its home market, demonstrating a -2.89% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Jiangxi Synergy Pharmaceutical Co Ltd's stock price CN¥6.71 by its total outstanding shares 419951495 (419.95 Million). Also see balance sheet size of Jiangxi Synergy Pharmaceutical Co Ltd for a full breakdown of the balance sheet.
Jiangxi Synergy Pharmaceutical Co Ltd Market Cap History: 2017 to 2026
Jiangxi Synergy Pharmaceutical Co Ltd's market capitalization history from 2017 to 2026. Data shows growth from $480.19 Million to $412.34 Million (2.52% CAGR). Also see cash efficiency ratio of Jiangxi Synergy Pharmaceutical Co Ltd for how efficiently the company converts equity into cash flow.
Jiangxi Synergy Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Jiangxi Synergy Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check 300636 stock price and chart for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.56x
Jiangxi Synergy Pharmaceutical Co Ltd's market cap is 0.56 times its annual revenue
Latest Price to Earnings (P/E) Ratio
6.31x
Jiangxi Synergy Pharmaceutical Co Ltd's market cap is 6.31 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $480.19 Million | $296.72 Million | $65.46 Million | 1.62x | 7.34x |
| 2018 | $279.96 Million | $267.12 Million | $24.53 Million | 1.05x | 11.41x |
| 2019 | $466.88 Million | $413.06 Million | $48.31 Million | 1.13x | 9.66x |
| 2020 | $568.78 Million | $435.42 Million | $70.05 Million | 1.31x | 8.12x |
| 2021 | $1.07 Billion | $592.13 Million | $81.12 Million | 1.80x | 13.17x |
| 2022 | $903.56 Million | $719.91 Million | $100.67 Million | 1.26x | 8.98x |
| 2023 | $645.23 Million | $722.14 Million | $105.98 Million | 0.89x | 6.09x |
| 2024 | $489.77 Million | $758.89 Million | $106.58 Million | 0.65x | 4.60x |
| 2025 | $461.51 Million | $828.66 Million | $73.09 Million | 0.56x | 6.31x |
Competitor Companies of 300636 by Market Capitalization
Companies near Jiangxi Synergy Pharmaceutical Co Ltd in the global market cap rankings as of September 19, 2026. Review 300636 intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Jiangxi Synergy Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #613 globally with a market cap of $44.92 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #670 globally with a market cap of $40.99 Billion USD ( CN¥280.10 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #613 | GALDERMA GROUP AG | NYSE:GALDY | $44.92 Billion | $38.53 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.90 |
| #670 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $40.99 Billion | CN¥43.91 |
Jiangxi Synergy Pharmaceutical Co Ltd Historical Marketcap From 2017 to 2026
Between 2017 and today, Jiangxi Synergy Pharmaceutical Co Ltd's market cap moved from $480.19 Million to $ 412.34 Million, with a yearly change of 2.52%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥412.34 Million | -10.65% |
| 2025 | CN¥461.51 Million | -5.77% |
| 2024 | CN¥489.77 Million | -24.09% |
| 2023 | CN¥645.23 Million | -28.59% |
| 2022 | CN¥903.56 Million | -15.40% |
| 2021 | CN¥1.07 Billion | +87.78% |
| 2020 | CN¥568.78 Million | +21.83% |
| 2019 | CN¥466.88 Million | +66.77% |
| 2018 | CN¥279.96 Million | -41.70% |
| 2017 | CN¥480.19 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Jiangxi Synergy Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $412.34 Million USD |
| MoneyControl | $412.34 Million USD |
| MarketWatch | $412.34 Million USD |
| marketcap.company | $412.34 Million USD |
| Reuters | $412.34 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Jiangxi Synergy Pharmaceutical Co Ltd
Jiangxi Synergy Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and fine chemicals in China and internationally. The company offers API products for anti-epilepsy and pain treatment, anti-inflammatory, gastrointestinal, anti-hypertension, anti-gout, anti-… Read more